Cordis acquires LuMend
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis Corp. will complement its endovascular portfolio with LuMend's Outback LTD reentry catheter and its Frontrunner XP CTO for use in minimally invasive procedures such as angioplasty and stenting. Cordis is banking on the Sept. 28-announced acquisition of the Redwood City, Calif.-based company to augment its presence in chronic total occlusions treatment...